Salame-Waxman D, Espinola-Zavaleta N, Carvajal-Juárez I, Alexandersón-Rosas E

Language: Spanish
References: 18
Page: 168-176
PDF size: 2490.30 Kb.

ABSTRACT

Despite technological advances, the prevention and oportunistic diagnosis of sarcoidosis, remains a challenge for physicians, since the clinical diagnosis is 5%, but it is very likely to occur in at least 40%, this being a serious problem of health even because there is no technique of choice for the diagnosis of cardiac sarcoidosis. In this review article, an overview of sarcoidosis will be presented at a later stage, focusing more on its cardiac involvement. The epidemiology with its different variations depending on the region where it occurs; subsequently the clinical manifestations both systemic because of sarcoidosis and those that occur specifically at cardiac level; besides the different diagnostic methods analyzing the benefits and disadvantages of each one; emphasizing the new existing proposals of which the PET with F-Fluorodeoxyglucose and MRI and the PET / MRI stand out. The best options around the clinical management and the prognosis that patients have with this disease.

REFERENCES

1. Walther J. Neumología clínica. 2.ªed. Madrid:Elsevier;2016.

2. Birnie D, Nery P, Ha A, Beanlands R. Cardiac Sarcoidosis. JACC. 2016;68:411-21.

3. Goldman L, Ausiello D, Goldman-Cecil SA. Tratado de medicina interna. 25.ªed.;2016.

4. Ferri F. Ferri's clinical advisor 2018:5 books in 1. 1.ªed. Elsevier;2017.

5. Guo X, Vittinghoff E, Vedantham V, Pletcher M, Lee B. Trends in Hospitalizations for Cardiac Sarcoidosis in the United States, 2005-2011. Circulation J. 2017;81:1739-41.

6. Sadda S, Hinton D, Schachat A, Wilkinson C, Weidemann P. Ryan's retina. 6th ed. 2017.

7. Hamzeh N, Wamboldt F, Weinberger H. Management of Cardiac Sarcoidosis in the United States. Chest. 2012;141:154-62.

8. Lazarus A. Sarcoidosis:Epidemiology, Etiology, Pathogenesis, and Genetics. Disease Mon. 2009;55:649-60.

9. Skalli H, Schulman A, Dorbala S. F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15:352.

10. Ohira H, Birnie DH, Pena E, Bernick J, Mc Ardle B, Leung E, et al. Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imag. 2016;43:259-69.

11. Kim JS, Judson MA, Donnino R, Gold M, Cooper LT, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9-21.

12. Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med. 2014;55:99-106.

13. Le Guludec D, Menad F, Faraggi M, Weinmann P, Battesti JP, Valeyre D. Myocardial sarcoidosis:clinical value of technetium-99m sestamibi tomoscintigraphy. Chest. 1994;106:1675-82.

14. Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995;107:330-4.

15. Hirose Y, Ishida Y, Hayashida K, Maeno M, Takamiya M, Ohmori F, et al. Myocardial involvement in patients with sarcoidosis:an analysis of 75 patients. Clin Nucl Med. 1994;19:522-6.

16. Eguchi M, Tsuchihashi K, Hotta D, Hashimoto A, Sasao H, Yuda S, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology. 2000;94:193-9.

17. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med. 2003;44:1030-6.

18. Lagana S, Parwani A, Nichols L. Cardiac Sarcoidosis A Pathology-Focused Review. Arch Pathol Lab Med. 2010;134(7):1039-46.